Regeneron Faces Downgrades After Melanoma Drug Fails to Beat Keytruda
Regeneron announced Friday that its phase 3 melanoma trial failed to outperform Merck's Keytruda, leading to a wave of analyst downgrades and a premarket stock decline on Monday.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) disclosed on Friday that its most closely watched phase 3 melanoma trial failed to meet its primary endpoint, triggering a wave of analyst downgrades and sending shares lower in premarket trading on Monday.
Trial Details
The trial aimed to show superiority of Regeneron's experimental drug over Merck's (MRK) Keytruda in advanced melanoma. Results showed the drug did not improve progression-free survival compared to the current standard of care.
Company Stance
Regeneron stated it will continue analyzing the data and present full results at a future medical conference. It noted the safety profile was acceptable, but efficacy fell short.
Analyst Reaction
Several analysts downgraded Regeneron stock, citing the removal of a key near-term catalyst. Price targets were also lowered.
Market Impact
Regeneron shares fell over 5% in premarket trading Monday. Merck shares were largely unchanged, as Keytruda remains the standard of care.
What This Means for Investors
The trial failure weakens Regeneron's pipeline and reduces near-term positive expectations. Investors may need to reassess the risk profile of biotech companies reliant on single pivotal trials.
Frequently Asked Questions
Found this useful? Share it